GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (LTS:0GP7) » Definitions » Enterprise Value

Medivir AB (LTS:0GP7) Enterprise Value : kr204.08 Mil (As of Jun. 10, 2024)


View and export this data going back to . Start your Free Trial

What is Medivir AB Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Medivir AB's Enterprise Value is kr204.08 Mil. Medivir AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-96.01 Mil. Therefore, Medivir AB's EV-to-EBIT ratio for today is -2.13.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Medivir AB's Enterprise Value is kr204.08 Mil. Medivir AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-93.27 Mil. Therefore, Medivir AB's EV-to-EBITDA ratio for today is -2.19.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Medivir AB's Enterprise Value is kr204.08 Mil. Medivir AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr7.73 Mil. Therefore, Medivir AB's EV-to-Revenue ratio for today is 26.39.


Medivir AB Enterprise Value Historical Data

The historical data trend for Medivir AB's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Enterprise Value Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 354.94 242.39 447.17 436.75 264.43

Medivir AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 437.88 394.21 415.91 264.43 174.41

Competitive Comparison of Medivir AB's Enterprise Value

For the Biotechnology subindustry, Medivir AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Medivir AB's Enterprise Value falls into.



Medivir AB Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Medivir AB's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Medivir AB's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medivir AB  (LTS:0GP7) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Medivir AB's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=204.078/-96.009
=-2.13

Medivir AB's current Enterprise Value is kr204.08 Mil.
Medivir AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-96.01 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Medivir AB's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=204.078/-93.268
=-2.19

Medivir AB's current Enterprise Value is kr204.08 Mil.
Medivir AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-93.27 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Medivir AB's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=204.078/7.734
=26.39

Medivir AB's current Enterprise Value is kr204.08 Mil.
Medivir AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr7.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medivir AB Enterprise Value Related Terms

Thank you for viewing the detailed overview of Medivir AB's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB (LTS:0GP7) Business Description

Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.

Medivir AB (LTS:0GP7) Headlines

No Headlines